GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,446.50p
   
  • Change Today:
    -1.50p
  • 52 Week High: 1,766.50p
  • 52 Week Low: 1,264.00p
  • Currency: UK Pounds
  • Shares Issued: 4,099.70m
  • Volume: 6,233,729
  • Market Cap: £59,302m
  • RiskGrade: 129

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Registrars: Equiniti
Brands: Lucozade, Horlicks, Ribena, Paxil, Seroxat

Key Personnel

CEO: Emma Walmsley
Chief Finance Officer: Julie Brown
Independent Non-Executive Director: Elizabeth (Liz) McKee Anderson
Independent Non-Executive Director: Anne Beal
Independent Non-Executive Director: Harry (Hal) C. Dietz
Independent Non-Executive Director: Vishal Sikka
Non-Executive Chairman: Jonathan Symonds
Senior Independent Non-Executive Director: Charles Bancroft
Non-Executive Dir: Jeannie Lee , Hal Barron , Gavin Screaton, Wendy Becker

Contact Details

Address: 79 New Oxford Street, London, United Kingdom, WC1A 1DG
Phone: +44 (0)20 8047 5000
Website: http://www.gsk.com

Listings

Sector: Pharma and Biotech(LSE)
Index: techMARK, FTSE 100, FTSE 350, FTSE All-Share
Overseas Listings: BATSLON:GSKL, NYSE:GSK
ISIN: GB00BN7SWP63

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,446.50p
Change Today -1.50p
% Change -0.10 %
52 Week High 1,766.50p
52 Week Low 1,264.00p
Volume 6,233,729
Shares Issued 4,099.70m
Market Cap £59,302m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
43.73% below the market average43.73% below the market average43.73% below the market average43.73% below the market average43.73% below the market average
27.66% above the sector average27.66% above the sector average27.66% above the sector average27.66% above the sector average27.66% above the sector average
Price Trend
14.81% above the market average14.81% above the market average14.81% above the market average14.81% above the market average14.81% above the market average
44.68% above the sector average44.68% above the sector average44.68% above the sector average44.68% above the sector average44.68% above the sector average
Income
74.83% above the market average74.83% above the market average74.83% above the market average74.83% above the market average74.83% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
37.19% below the market average37.19% below the market average37.19% below the market average37.19% below the market average37.19% below the market average
48.39% below the sector average48.39% below the sector average48.39% below the sector average48.39% below the sector average48.39% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 14
Sell 3
Strong Sell 1
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 28-May-2025

Time Volume / Share Price
15:25 1 @ 1,451.00p
15:08 1 @ 1,453.00p
15:08 1 @ 1,453.00p
15:08 1 @ 1,453.00p
15:18 2 @ 1,450.50p

GSK Key Personnel

CEO Emma Walmsley

Top of Page